News from labrys biologics inc

Jan 08, 2014, 08:00 ET

Labrys Biologics Initiates Two Phase 2 Studies of LBR-101 for the Prevention of Chronic and Episodic Migraine

Labrys Biologics Inc., a biotechnology company focused on treatments for migraine, today announced that patients are now being enrolled in two...

Jun 26, 2013, 08:00 ET

Labrys Biologics Presents LBR-101 Late-breaking Data at 2013 International Headache Congress

 Labrys Biologics Inc., a biotechnology company focused on treatments for chronic migraine, today announced data from three late-breaking...

Mar 18, 2013, 08:00 ET

Labrys Biologics Announces Key Executive Appointments

Labrys Biologics Inc., a company focused on treatments for chronic migraine, today announced key executive appointments to lead the development of...

Jan 03, 2013, 07:30 ET

Labrys Biologics Secures $31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer

Labrys Biologics Inc., a company focused on treatments for chronic migraine, today announced the completion of a $31 Million Series A financing...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
ReportBuyer
Investor-Edge